The reverse stock split will be implemented in connection with the company’s intention to uplist the company's common stock to the NYSE American. The reverse split is intended to fulfill the stock price requirements for a listing on the
Post-split, the company’s common stock will begin trading under the symbol “HYEXD” to indicate its post-split status. After 20 business days, the stock will return to trading under the symbol “HYEX.”
“This reverse split represents another major step toward our common stock being traded on a listed
“These benefits will be timely, as we prepare to announce a number of new products that will leverage our multiple sales and distribution channels and our broadening customer base, and as we continue to pursue growth both organically and through strategic acquisitions that can also leverage our broad distribution platform.”
Over the last year,
As a result of the split, every 120 shares of issued and outstanding common stock will be exchanged for one share of common stock. Each stockholder’s percentage ownership interest in
The reverse stock split will reduce the number of shares of issued and outstanding common stock from 354,492,442 pre-split to approximately 2,954,172 post-split. Proportional adjustments will be made to any outstanding warrants or options.
About NYSE American
Drawing on its heritage as the
About
The company’s subsidiaries, BergametNA™ and Ultimate Brain Nutrients™ (UBN), offer nutraceutical natural heart and brain health supplements. This includes the only heart health supplement distributed in
UBN’s KETONOMICS® proprietary formulations, which have been designed to enhance brain activity, focus, headache and cognitive behavior, provide many sales and intellectual property licensing opportunities.
For more information visit: healthyextractsinc.com, bergametna.com or tryubn.com.
Forward-Looking Statements and Safe Harbor Notice
All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K filed with the
Food & Drug Administration Disclosure
The product and formulation featured in this release is not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctor’s advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.
BergametNA™, Ultimate Brain Nutrients™, UBN™, Citrus Bergamot SuperFruit™ and F4T® are registered trademarks of Healthy Extracts Inc.™
Company Contact
Tel (720) 463-1004
Email contact
Investor Contact
CMA Investor Relations
Tel (949) 432-7566
Email contact
Media Contact:
CMA Media Relations
Tel (949) 432-7572
Email Contact
Source:
2023 GlobeNewswire, Inc., source